Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy

Journal of Clinical Rheumatology

Volumn 25, Issue 8, 2019, Pages 329-334

  Intongkam, Samanan ^a   Parinya, Samakarnthai ^a   Pakchotanon, Rattapol ^a   Narongroeknawin, Pongthorn ^a   Assavatanabodee, Paijit ^a   Chaiamnuay, Sumapa ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

disease modifying antirheumatic drugs; hepatitis B vaccination; rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT HEPATITIS B VACCINE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOLOGIC FACTOR; PHARMACOLOGICAL BIOMARKER; RECOMBINANT VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DAS28; DISEASE DURATION; DISEASE EXACERBATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VACCINATION; VACCINE IMMUNOGENICITY; VISUAL ANALOG SCALE; BLOOD; IMMUNOLOGY; THAILAND; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOMARKERS, PHARMACOLOGICAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RITUXIMAB; THAILAND; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 85075538360     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000877     Document Type: Article

References (24)

1. Chaiamnuay P, Darmawan J, Muirden KD,. Epidemiology of rheumatic disease in rural Thailand: A WHO-ILAR COPCORD study. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol. 1998; 25: 1382-1387.
2. Hochberg MC, Johnston SS, John AK,. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008; 24: 469-480.
3. O'Dell JR,. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004; 350: 2591-2602.
4. Doran MF, Crowson CS, Pond GR,. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2294-2300.
5. Van Assen S, Elkayam O, Agmon-Levin N,. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011; 10: 341-352.
6. Zhuang GH, Yan H, Wang XL,. [A five-year observation on efficacy of revaccination in children of non-response to hepatitis B vaccine]. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]. 2006; 40: 8-12.
7. Rahier JF, Moutschen M, van Gompel A,. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010; 49: 1815-1827.
8. Singh JA, Furst DE, Bharat A,. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64: 625-639.
9. Gross K, Combe C, Kruger K,. Arthritis after hepatitis B vaccination. Report of three cases. Scand J Rheumatol. 1995; 24: 50-52.
10. Vautier G, Carty JE,. Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination. Br J Rheumatol. 1994; 33: 991.
11. Pope JE, Stevens A, Howson W,. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol. 1998; 25: 1687-1693.
12. Elkayam O, Yaron M, Caspi D,. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002; 61: 623-625.
13. Darawankul B, Chaiamnuay S, Pakchotanon R,. The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: Results from the TARAC cohort. Clin Rheumatol. 2015; 34: 43-49.
14. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A,. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107: 1460-1466.
15. Andrade P, Santos-Antunes J, Rodrigues S,. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015; 30: 1591-1595.
16. Belle A, Baumann C, Bigard MA,. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2015; 27: 877-881.
17. Oren S, Mandelboim M, Braun-Moscovici Y,. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. Ann Rheum Dis. 2008; 67: 937-941.
18. Bingham CO 3rd, Looney RJ, Deodhar A,. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum. 2010; 62: 64-74.
19. Van Assen S, Holvast A, Benne CA,. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010; 62: 75-81.
20. Arad U, Tzadok S, Amir S,. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011; 29: 1643-1648.
21. Kapetanovic MC, Roseman C, Jönsson G,. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011; 63: 3723-3732.
22. Hua C, Barnetche T, Combe B,. Effect of methotrexate, anti-tumor necrosis factor α and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014; 66: 1016-1026.
23. Kumar R, Burns EA,. Age-related decline in immunity: Implications for vaccine responsiveness. Expert Rev Vaccines. 2008; 7: 467-479.
24. Painter SD, Ovsyannikova IG, Poland GA,. The weight of obesity on the human immune response to vaccination. Vaccine. 2015; 33: 4422-4429.